Skip to content
Regramostim
Regramostim is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
705 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanomaD008545233951362
LeukemiaD007938C95113771255
LymphomaD008223C85.9153841155
Prostatic neoplasmsD011471C6119293143
NeuroblastomaD009447EFO_0000621102651442
Myeloid leukemia acuteD015470C92.0121731130
Non-hodgkin lymphomaD008228C85.93541215
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.0351210
Covid-19D000086382U07.124117
Hematologic neoplasmsD01933722126
Show 12 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5024333254
Myelodysplastic syndromesD009190D4615204235
Multiple myelomaD009101C90.012174232
Hiv infectionsD015658EFO_0000764B201232420
Plasma cell neoplasmsD054219613118
Pancreatic neoplasmsD010190EFO_0003860C25681115
GlioblastomaD005909EFO_000051567114
SarcomaD01250927211
Renal cell carcinomaD0022923518
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_00003404418
Show 27 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80152334
Colorectal neoplasmsD01517991519
Lung neoplasmsD008175C34.9079218
Ovarian neoplasmsD010051EFO_0003893C56810117
Non-small-cell lung carcinomaD002289310113
Central nervous system neoplasmsD016543369
Kidney neoplasmsD007680EFO_0003865C64389
Fallopian tube neoplasmsD005185448
Liver neoplasmsD008113EFO_1001513C22.0548
Myeloproliferative disordersD009196D47.13518
Show 100 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinson diseaseD010300EFO_0002508G2033
Rheumatoid arthritisD001172EFO_0000685M06.922
Kaposi sarcomaD012514C4622
Wilms tumorD00939622
Diffuse intrinsic pontine gliomaD00008044322
MedulloblastomaD00852722
AstrocytomaD001254EFO_000027122
OligodendrogliomaD009837EFO_000063122
Biphenotypic leukemia acuteD015456C95.011
Coronary artery diseaseD003324I25.111
Show 30 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Autologous transplantationD01418222
Residual neoplasmD01836511
Acute liver failureD01711411
Multiple organ failureD009102EFO_100137311
InflammationD00724911
EndotoxemiaD01944611
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameREGRAMOSTIM
INNregramostim
Description
Regramostim is a protein pharmaceutical. It is currently being investigated in clinical studies.
Classification
Protein
Drug classcolony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF); colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL2107881
ChEBI ID
PubChem CID
DrugBank
UNII IDKR89Q40F01 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 14 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details